Company news

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) news

Oramed Pharmaceuticals Inc. news releases on 6ix. Latest, Jun 25, 2026: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index…

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) news

Press releases & updates

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Lifeward Successfully Closes on Strategic Partnership with Oramed

Oramed and Lifeward Announce Strategic Transaction

Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company

Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

Oramed Reports Fiscal Third Quarter 2025 Financial Results

ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

Oramed Pharmaceuticals Issues Letter to Shareholders

Oramed Pharmaceuticals : Ancillary Agreement Completion Protocol and Supplemental Agreement

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

Oramed Pharmaceuticals : Reception of an additional payment from Scilex Holding Company

Oramed Pharmaceuticals : INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTSAS OF SEPTEMBER 30, 2024

Oramed Pharmaceuticals : Announces Restructuring of Scilex Holding Company Debt Form 8 K

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

Oramed Pharmaceuticals : Submission of Matters to a Vote of Security Holders Form 8 K

Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock

Oramed Letter to Shareholders

Oramed Pharmaceuticals : Received an additional payment from Scilex

ORAMED PHARMACEUTICALS : 2023 ANNUAL REPORT

Oramed Pharmaceuticals : PROXY STATEMENT OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 1, 2024

Oramed Pharmaceuticals : Management Change/Compensation - Form 8-K

Oramed Pharmaceuticals : Update on the receipt of payments for the Scilex transaction

Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

Oramed to Present at the 83rd American Diabetes Association Conference

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

Oramed Appoints Ben Shapiro to its Board of Directors

Oramed Pharmaceuticals Issues Shareholder Update

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea

Oramed Reports Third Quarter 2022 Financial Results

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

Oramed to Present at H.C. Wainwright Global Investment Conference

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

Oramed Granted NASH Patent in Europe